文献速递支持与姑息治疗骨软组织肉瘤与黑色素瘤

儿童癌症长期幸存者后续肿瘤风险中癌症治疗与遗传易感性的贡献:圣裘德终身队列与儿童癌症幸存者研究报告

Contributions of cancer treatment and genetic predisposition to risk of subsequent neoplasms in long-term survivors of childhood cancer: a report from the St Jude Lifetime Cohort and the Childhood Cancer Survivor Study.
PubMed 文献 · Lancet Oncol · 2025-01-01

该研究分析圣裘德终身队列(SJLIFE,4401人)和儿童癌症幸存者研究(CCSS,7943人)共12344名幸存者,使用多变量分段指数模型计算归因分数。癌症治疗与遗传风险共同贡献了30%(肉瘤)至92%(脑膜瘤)的后续肿瘤归因分数,生活方式因素贡献可忽略。

要点

  • 癌症治疗与遗传风险共同贡献后续肿瘤归因分数30%(肉瘤)至92%(脑膜瘤)
  • 高剂量放疗贡献最大,≥35岁随访期归因分数44.7% vs <35岁40.0%
  • 基于PRS的遗传风险贡献1%(脑膜瘤)至52%(甲状腺癌),超过化疗贡献

核心结论

  • 癌症治疗与遗传易感性是儿童癌症幸存者后续肿瘤风险的主要贡献因素,生活方式因素似乎影响极小。

研究设计与样本

  • 分析两个回顾性构建队列(持续招募并前瞻性随访):SJLIFE(4401人;NCT00760656)和CCSS(7943人;NCT01120353),共12344名符合分析条件的幸存者。
  • 使用多变量分段指数模型计算归因分数,评估放疗、化疗、遗传易感性(PRS最高两个三分位与最低三分位比较)和生活方式因素对首次后续肿瘤发生的贡献。
  • 研究于2024年1月1日至2024年9月30日进行。

主要发现

  • 癌症治疗与遗传风险共同贡献后续肿瘤归因分数范围为30%(95%CI 6-49;肉瘤)至92%(89-94;脑膜瘤)。
  • 较高放疗暴露贡献最大,≥35岁随访期SJLIFE后续肿瘤归因分数44.7%(95%CI 41.9-47.5),<35岁为40.0%(37.1-43.3)。
  • 基于PRS的遗传风险归因分数范围为1%(95%CI 0-7;脑膜瘤)至52%(39-62;甲状腺癌),超过化疗的3%(1-6;SMNs)至35%(19-49;肉瘤)。
  • 生活方式因素贡献可忽略。
  • SJLIFE中位年龄33.0岁(IQR 24.1-42.1),CCSS中位年龄36.0岁(29.5-43.6);男性6127人(49.6%),女性6217人(50.4%);白人10907人(88.4%)。

临床怎么用

  • 作者认为,结果强调在为该脆弱人群制定有效风险评估和监测策略时需同时考虑治疗史和遗传因素。
  • 原文未据此给出具体临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Survivors of childhood cancer are at risk of subsequent neoplasms (SNs) associated with exposure to radiotherapy and chemotherapy, as well as with genetic predisposition. We aimed to estimate the relative contributions of these risk factors to the total SN burden in survivor populations. METHODS: We analysed data from two retrospectively constructed cohorts with ongoing recruitment and prospective follow-up: the St Jude Lifetime Cohort (SJLIFE; 4401 participants; NCT00760656) and the Childhood Cancer Survivor Study (CCSS; 7943 participants; NCT01120353). We used multivariable piecewise-exponential models to calculate attributable fractions to assess the contributions of radiotherapy and chemotherapy exposures, genetic predisposition (comparing the top two tertiles with the lowest tertile of polygenic risk scores [PRSs] where the tertile is from external general population corresponding to SN outcome) and lifestyle factors (physical activity, smoking, alcohol consumption, obesity, and diet) to incident of the first occurrences of SNs as the primary outcome. FINDINGS: The study was conducted between Jan 1, 2024, and Sept 30, 2024. Of the 12 344 survivors eligible for analysis, median attained age was 33·0 years (IQR 24·1-42·1) in SJLIFE and 36·0 years (29·5-43·6) in CCSS; 6127 (49·6%) were men and 6217 (50·4%) were women. Most patients were White (10 907 [88·4%]). The median follow-up from primary cancer diagnosis was 24·2 years (IQR 11·7-35·4) in SJLIFE (from Sept 13, 2007 to April 20, 2020) and 28·0 years (8·9-37·2) in CCSS (from Jan 1, 1975 to Dec 31, 2023). Cancer treatments and genetic risk jointly contributed to a substantial proportion of incident SN cases with attributable fractions ranging from 30% (95% CI 6-49; sarcoma) to 92% (89-94; meningioma). Higher exposure levels of radiotherapy contributed most, particularly in older (≥35 years; SJLIFE proportion of SNs 44·7% [95% CI 41·9-47·5]) compared with younger (<35 years; 40·0% [37·1-43·3]) follow-up age periods. Elevated genetic risk based on the PRSs accounted for a notable proportion, ranging from 1% (95% CI 0-7; meningioma) to 52% (39-62; thyroid cancer), surpassing contributions of chemotherapies, ranging from 3% (1-6; SMNs) to 35% (19-49; sarcoma). Lifestyle factors contributed negligibly. INTERPRETATION: Cancer treatments and genetic predisposition are primary contributors to the risk of SNs in childhood cancer survivors, and lifestyle factors seem to have a minimal effect. These results highlight the crucial need to consider both treatment history and genetic factors in developing effective risk assessment and surveillance strategies for this vulnerable population. FUNDING: US National Institutes of Health and the American Lebanese Syrian Associated Charities.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Neupane A, Liu Q, Taneja S, et al. Contributions of cancer treatment and genetic predisposition to risk of subsequent neoplasms in long-term survivors of childhood cancer: a report from the St Jude Lifetime Cohort and the Childhood Cancer Survivor Study. Lancet Oncol. 2025. PMID: 40449499. doi:10.1016/S1470-2045(25)00157-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。